Home » Novartis’ Ilaris Earns FDA Approval for Rare Autoinflammatory Disease
Novartis’ Ilaris Earns FDA Approval for Rare Autoinflammatory Disease
Novartis’ Ilaris (canakinumab) has received FDA approval for treatment of active Still’s disease, including adult-onset Still’s disease (AOSD).
The anti-inflammatory drug is the first approved treatment for AOSD, a rare type of inflammatory arthritis that features fevers, rash and joint pain.
Ilaris had received a priority review from the agency. The drug was previously approved for treatment of systemic juvenile idiopathic arthritis in patients aged 2 years and older.
Upcoming Events
-
07May
-
14May
-
30May